Management of this condition has been associated with antibiotic misuse. In the latest Bench to Bedside column, clinicians offer insights on therapy indications and what the latest literature reports on the condition.
Management of necrotizing pancreatitis is challenging and has been associated with an overuse and misuse of antibiotics.1 Most patients with sterile necrotizing pancreatitis can be managed without intervention (ie, necrosectomy or percutaneous drainage) and without antibiotics.2-10 Additionally, randomized controlled trials have failed to show the benefit of prophylactic antibiotics in the setting of acute and necrotizing pancreatitis.2,3
In the setting of infected necrotizing pancreatitis, however, antibiotics are universally recommended.4-12 Diagnosis of infected necrotizing pancreatitis is difficult as the inflammatory process seen in severe pancreatitis may be indistinguishable from infection. Clinical signs and symptoms of infection (ie, persistent fever, abdominal pain, elevated procalcitonin) and imaging showing gas in peripancreatic tissues are considered evidence of infected necrotizing pancreatitis (Table 1).6-8,11,13
Once a diagnosis of infected necrotizing pancreatitis is made, antibiotics should be started as part of a comprehensive treatment strategy that includes hydration, pain control, nutritional support, and surgical intervention when necessary. Multiple guidelines recommend the use of carbapenems as treatment of infected necrotizing pancreatitis largely based on pharmacokinetic data from the 1980s and 1990s demonstrating imipenem’s ability to penetrate pancreatic tissue.14-16 However, non-carbapenem beta-lactams (ie, ceftriaxone, cefepime, piperacillin-tazobactam) may also be considered as part of the pancreatic treatment arsenal based on pharmacokinetic data published later demonstrating adequate pancreatic concentrations.17
Antibiotic Choice: What do the Guidelines Say?
Various national and international guidelines have addressed the management of infected necrotizing pancreatitis (Figure 1).4-12,14-16,18,19 Most suggest utilizing antibiotics known to penetrate pancreatic necrosis.5,8,10 The 2013 American College of Gastroenterology Guideline (ACG) on the Management of Acute Pancreatitis recommends carbapenems, quinolones, and metronidazole, a conditional recommendation based on low quality of evidence.5 Interestingly, this same guideline also mentions that antibiotics shown to penetrate pancreatic tissue in clinical trials include carbapenems, quinolones, metronidazole, and high-dose cephalosporins. The 2018 European Society of Gastrointestinal Endoscopy (ESGE) Guideline also includes high-dose cephalosporins as a treatment option for infected necrotizing pancreatitis.8 The 2019 World Society of Emergency Surgery (WSES) guidelines recommend that carbapenems should be used only in very critically ill patients due to the spread of carbapenem-resistant Klebsiella pneumoniae.10
The Ideal Antibiotic: What Does the Data Say?
Ideal antibiotics for the management of infected necrotizing pancreatitis include those with activity against gastrointestinal commensal bacteria and penetrate necrotic pancreatic tissue.8 Pharmacokinetic characteristics favorable for penetrating necrotic pancreatic tissue include high lipophilicity and a large volume of distribution. Early human studies investigating antibiotic penetration into pancreatic tissues often included metronidazole, quinolones, and carbapenems, which all demonstrated penetration of necrotic pancreatic tissue and achieved concentrations above typical minimum inhibitory concentrations (MICs) for most pathogens of concern.14-16 In later years, cefepime, piperacillin-tazobactam, and ceftriaxone were also investigated for their abilities to penetrate necrotic pancreatic tissues (Table 2).
In 1997, Ceftriaxone pancreatic concentrations were collected from 10 pancreatic surgery patients following a single 1g dose.20 In most patients, concentrations were greater than MICs for common pathogens. In 2001, cefepime pancreatic concentrations were measured from nine patients who received a single 2g dose of cefepime.21 Results showed high cefepime concentrations in pancreatic pseudocyst fluid, pancreatic tissue, and pancreatic fistula fluid and concluded potential use of cefepime in the treatment of pancreatic infections. Additional studies have also shown adequate cefepime pancreatic concentrations.22,23 In 2006, piperacillin-tazobactam pancreatic concentrations were measured from 15 patients with acute necrotizing pancreatitis, which showed effective penetration into necrotic pancreatic tissue and to inflammatory ascites surrounding the pancreas.18
Conclusion
In the setting of infected pancreatitis, antibiotics should be utilized as part of a multimodal treatment strategy. Carbapenem-sparing regimens include piperacillin-tazobactam, cefepime plus metronidazole, or ceftriaxone plus metronidazole. Fluoroquinolones may be considered as oral step down for treatment; however, they should be reserved for select cases due to the prevalence of resistance and potential collateral damage.
References
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.